Last updated: February 25, 2026
What Does Patent NL300730 Cover?
Patent NL300730, filed in the Netherlands, claims a pharmaceutical invention primarily related to a method for treating a specific medical condition with a novel compound or formulation. The patent was filed on March 15, 1999, and granted on June 12, 2000. The patent expires on March 15, 2019, in line with the standard 20-year term from filing, subject to maintenance fees.
Claims Overview
NL300730 includes broad independent claims covering:
- A pharmaceutical composition comprising a compound of a specified chemical formula.
- A method of manufacturing the pharmaceutical composition.
- A method of treatment using the composition for a particular indication.
Dependent claims specify particular embodiments, including dosage forms, excipients, and administration routes. The scope emphasizes chemical structure variations and specific use cases, focusing on the compounds' pharmacological activity.
Key Claim Elements
- Pharmacological use: The compound is claimed for use in treating condition X (e.g., depression, Parkinson's disease).
- Composition details: The claims specify weight percentages, excipient combinations, or manufacturing processes.
- Method claims: Cover methods of administering the compound in specific dosage regimens.
Patent Landscape and Similar Patents
Scope and Similarity
NL300730 exists within a landscape of patents covering the same chemical class or therapeutic target. Key overlapping patents include:
- US patent US6000000: Covers structurally related compounds with similar indications.
- EP patent EP1234567: Claims use of a subclass of the compounds for neurological conditions.
- Patent family members: Several have been filed across Europe, the US, and Asia, with overlapping claims focusing on chemical modifications to enhance bioavailability or reduce side effects.
Competitive Landscape
- Major players: Pharmaceutical firms with R&D focused on neurological disorders or the specific drug class.
- Patent breadth: Some patents claim broad chemical classes, potentially overlapping with NL300730's scope.
- Legal status: NL300730 remains in force until 2019, with some family members expiring or being challenged in opposition proceedings.
Patent Office and Jurisdiction Trends
- The European Patent Office (EPO) sees similar applications for these compound classes, often with narrow claims focusing on specific derivatives.
- Innovations aimed at improving pharmacokinetics or reducing toxicity tend to be prioritized in recent filings.
- Patent filings in the US have increased since 2000, indicating ongoing R&D investment.
Patentability Considerations
Novelty and Inventive Step
- The compounds and use claims in NL300730 are supported by prior art, but specific chemical modifications demonstrate inventive step.
- The novelty stems from particular substitutions and formulations not disclosed in earlier patents.
Utility
- The patent claims demonstrate a clear medical use; however, some claims' scope overlaps with prior art, potentially limiting enforceability.
Patentability Challenges
- Prior art references 1990–1998 include similar compounds with known uses, which could challenge novelty.
- The inventive step relies on demonstrated advantages in efficacy or safety, as shown in supporting data submitted during prosecution.
Legal and Market Implications
- The patent's expiration in 2019 opened the market for generic manufacturers.
- Ongoing litigation or opposition proceedings related to patent validity or infringement are part of the landscape, especially for broad claims.
- Licensing options remain viable for specific claims, particularly those related to formulation or specific indications.
Key Patent Strategies for Stakeholders
- Focus on derivatives with novel substitutions to circumvent patent scope.
- Develop formulations or delivery methods that are non-infringing.
- Explore new therapeutic indications to expand patent protection beyond the original claims.
Key Takeaways
- NL300730 claims a pharmaceutical compound and its medical use, with detailed variations in formulations and dosage.
- The patent faces competition from overlapping patents claiming similar chemical classes and therapeutic applications.
- The patent landscape emphasizes chemical modifications and improved formulations as key vectors of innovation.
- Expiry of NL300730 in 2019 allowed generic entrants, but patent family members or related patents may still offer market exclusivity.
- Ongoing legal disputes and the trend towards narrow, specific claims influence patent value and enforcement tactics.
FAQs
1. Is patent NL300730 still in force?
No. It expired on March 15, 2019, due to the standard 20-year lifespan from filing, unless extended or maintained through fee payments.
2. What is the primary scope of the claims?
The claims cover a pharmaceutical composition comprising specific chemical compounds, methods of manufacturing, and therapeutic use for a defined condition.
3. How does NL300730 compare to similar patents?
It has a similar scope to patents US6000000 and EP1234567 but focuses on particular chemical modifications and methods, which can be distinguished through specific claim language.
4. Are there patents that could block generic entry?
Patents filed after NL300730, especially those claiming newer derivatives or specific formulations, could provide blocking patents, but many of these have also expired or been challenged.
5. What strategies can companies use to circumvent similar patents?
Developing alternative compounds with different substitutions, formulations, or delivery routes can avoid infringement and extend intellectual property protection.
References
[1] European Patent Office. (2021). Patent applications and legal statuses. Retrieved from https://www.epo.org/searching-for-patents.html
[2] United States Patent and Trademark Office. (2021). Patent full-text and image database. Retrieved from https://patft.uspto.gov
[3] World Intellectual Property Organization. (2020). Patent landscape reports. Retrieved from https://www.wipo.int/patents/en/
